IP Library Granted Patent US 7,625,903
Granted Patent B2
US 7,625,903 · App. 12/019,730 · Granted Dec 1, 2009

Anthranilamide inhibitors of Aurora kinase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,625,903
App. No.
12/019,730
Granted
Dec 1, 2009
Kind
B2
Abstract

The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; where R 1 , R 2 , R 3 , R 4 , r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.

Claims (4)

1. A compound or a pharmaceutically acceptable salt thereof, which compound is N-(1-methylethyl)-2-[(5-methyl-2-{[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)amino]benzamide.

2. The compound of claim 1 .

3. The pharmaceutically acceptable salt of the compound of claim 1 .

4. A composition comprising a) the compound of claim 1 or a pharmaceutically acceptable salt thereof; and b) at least one pharmaceutically acceptable excipient.

Assignments (2)
CHANGE OF NAME Recorded Jan 6, 2010
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 023731/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2008
From: JOHNSON, NEIL W.; BRYAN, DEBORAH L.
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 021475/0588 →